BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 33075738)

  • 1. Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs).
    Mirvis E; Toumpanakis C; Mandair D; Gnanasegaran G; Caplin M; Navalkissoor S
    Lung Cancer; 2020 Dec; 150():70-75. PubMed ID: 33075738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.
    Shin Y; Moon BH; Ryoo BY; Chang HM; Kim KP; Hong YS; Kim TW; Ryu JS; Kim YI; Yoo C
    Target Oncol; 2024 Jan; 19(1):41-49. PubMed ID: 38108953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).
    Baum RP; Wang P; Jakobsson V; Zhao T; Schuchardt C; Khong PL; Zhang J
    Theranostics; 2024; 14(1):133-142. PubMed ID: 38164147
    [No Abstract]   [Full Text] [Related]  

  • 4. Radiopharmaceuticals used for diagnosis and therapy of NETs.
    Papachristou M
    Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant
    Ballal S; Yadav MP; Tripathi M; Sahoo RK; Bal C
    J Nucl Med; 2022 Jul; ():. PubMed ID: 35863893
    [No Abstract]   [Full Text] [Related]  

  • 6. The efficacy, toxicity and survival of salvage retreatment PRRT with
    Sitani K; Parghane R; Talole S; Basu S
    Br J Radiol; 2022 Sep; 95(1137):20210896. PubMed ID: 35816545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis.
    Friebe L; Freitag MT; Braun M; Nicolas G; Bauman A; Bushnell D; Christ E; Wild D
    J Nucl Med; 2024 Feb; 65(2):228-235. PubMed ID: 38164592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by
    Al Mansour L; De Mestier L; Haissaguerre M; Afchain P; Hadoux J; Lecomte T; Morland D; Cottereau AS; De Rycke O; Tlili G; Tordo J; Janier M; Deville A; Walter T
    J Nucl Med; 2024 Feb; 65(2):258-263. PubMed ID: 38212066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of
    Bodei L; Raj N; Do RK; Mauguen A; Krebs S; Reidy-Lagunes D; Schöder H
    J Nucl Med; 2023 Apr; 64(4):567-573. PubMed ID: 36396457
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Sharma R; Wang WM; Yusuf S; Evans J; Ramaswami R; Wernig F; Frilling A; Mauri F; Al-Nahhas A; Aboagye EO; Barwick TD
    Radiother Oncol; 2019 Dec; 141():108-115. PubMed ID: 31542317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, Toxicity, and Prognostic Factors of Re-treatment With [177Lu]Lu-DOTA-TATE in Patients With Progressing Neuroendocrine Tumors: The Experience of a Single Center.
    Silva MM; Canha M; Salazar D; Neves JS; Ferreira G; Carvalho D; Duarte H
    Cureus; 2023 Oct; 15(10):e47506. PubMed ID: 38021538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
    Love C; Desai NB; Abraham T; Banks KP; Bodei L; Boike T; Brown RKJ; Bushnell DL; DeBlanche LE; Dominello MM; Francis T; Grady EC; Hobbs RF; Hope TA; Kempf JS; Pryma DA; Rule W; Savir-Baruch B; Sethi I; Subramaniam RM; Xiao Y; Schechter NR
    Clin Nucl Med; 2022 Jun; 47(6):503-511. PubMed ID: 35507433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors.
    Assi HA; Hornbacker K; Shaheen S; Wittenberg T; Silberman R; Kunz PL
    Pancreas; 2021 Jul; 50(6):890-894. PubMed ID: 34398071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of long-acting somatostatin analogues on the uptake of [
    Veerman CHAM; Siebinga H; de Vries-Huizing DMV; Tesselaar MET; Hendrikx JJMA; Stokkel MPM; Aalbersberg EA
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1434-1441. PubMed ID: 36598536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cycle effect quantified: reduced tumour uptake in subsequent cycles of [
    Siebinga H; Hendrikx JJMA; de Vries-Huizing DMV; Huitema ADR; de Wit-van der Veen BJ
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):820-827. PubMed ID: 37843598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting the survival probability of functional neuroendocrine tumors treated with peptide receptor radionuclide therapy: Serbian experience.
    Vukomanovic V; Nedic KV; Radojevic MZ; Dagovic A; Milosavljevic N; Markovic M; Ignjatovic V; Simic Vukomanovic I; Djukic S; Sreckovic M; Backovic M; Vuleta M; Djukic A; Vukicevic V; Ignjatovic V
    Front Endocrinol (Lausanne); 2023; 14():1270421. PubMed ID: 38317712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 177 Lu-DOTATATE PRRT for Multiple Unusual Metastatic Sites in Neuroendocrine Tumor.
    Parghane RV; Basu S
    Clin Nucl Med; 2022 Oct; 47(10):874-875. PubMed ID: 35353741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
    Love C; Desai NB; Abraham T; Banks KP; Bodei L; Boike T; Brown RKJ; Bushnell DL; DeBlanche LE; Dominello MM; Francis T; Grady EC; Hobbs RF; Hope TA; Kempf JS; Pryma DA; Rule W; Savir-Baruch B; Sethi I; Subramaniam RM; Xiao Y; Schechter NR
    Am J Clin Oncol; 2022 Jun; 45(6):233-242. PubMed ID: 35507413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
    Sukrithan V; Armbruster H; Rogers S; Vogt SM; Grenade C; Verschraegen C; Zhou Y; Goyal A; Natwa M; Hussein A; Barr H; Konate D; Batdorf R; Brown A; Williams B; Zhao S; Wei L; Xu M; Shah MH; Konda B
    PLoS One; 2024; 19(5):e0298824. PubMed ID: 38748739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE: Nursing Roles in Managing Patients With Gastroenteropancreatic Neuroendocrine Tumors.
    Bennett B; Gardner L; Ryan P
    Clin J Oncol Nurs; 2024 Jan; 28(1):79-87. PubMed ID: 38252861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.